ArticleJournal for immunotherapy of cancer2022
Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.